Filing summary
Company identity warning: The request identifies LENZ Therapeutics, Inc., but the supplied Form 10-Q is for Graphite Bio, Inc. (Nasdaq: GRPH). This summary describes the filing text provided and should not be attributed to LENZ without verifying the filing.
Business context and reporting period
Unaudited results cover the three months ended March 31, 2022; the filing was signed May 12, 2022. Graphite Bio is a clinical-stage gene-editing company with no product sales or approved products. Its lead candidate, GPH101, is being developed for sickle cell disease (SCD); other programs remain preclinical or earlier-stage.
Financial and operating metrics
- Revenue: No product-sales revenue; the filing reports no revenue-generating commercial products.
- Operating expenses: $26.0 million, up from $9.4 million in Q1 2021. Research and development was $18.2 million (prior year $5.4 million); general and administrative expense was $7.7 million (prior year $4.0 million).
- Loss: Net loss attributable to common stockholders was $25.8 million, versus $19.7 million a year earlier. Comprehensive loss was $26.1 million, including $0.3 million of unrealized investment losses. Basic and diluted loss per share was $0.48, compared with $5.75; the share count increased substantially after the 2021 IPO and preferred-stock conversion.
- Cash flow: Operating cash use was $21.2 million, versus $8.1 million. Investing cash use was $170.7 million, mainly reflecting purchases of marketable securities and $3.3 million of property and equipment. There were no financing cash flows in Q1 2022; Q1 2021 included $165.8 million of financing proceeds.
- Liquidity: Cash, cash equivalents and marketable securities totaled $352.1 million at March 31, 2022, compared with cash and cash equivalents of $377.0 million at December 31, 2021. Current assets were $343.8 million and current liabilities $12.8 million. Accumulated deficit was $167.2 million.
- Debt and leases: The filing reports no borrowings in the presented balance sheet. Operating lease liabilities totaled $10.2 million; separately, a not-yet-commenced 10-year Bayside facility lease carries $81.0 million of future minimum payments.
- Margins: Not meaningful because the company had no product revenue.
Changes versus the prior comparable period
- R&D expense increased $12.9 million, principally from clinical-trial and contract-manufacturing activity, personnel costs, facilities and lease costs.
- G&A expense increased $3.7 million, reflecting hiring and related stock-based compensation, professional services and insurance.
- Q1 2021 included a $10.3 million loss from remeasurement of a preferred-stock tranche liability; there was no such charge in Q1 2022. Q1 2022 instead included $0.1 million of other income, principally investment-related.
- Cash and investments shifted from predominantly cash at year-end 2021 to a portfolio that included $167.0 million of U.S. Treasury marketable securities at quarter-end. Unrealized investment losses were $0.3 million.
Outlook, risks and unusual items
- Management expected the March 31 cash, cash equivalents and investments to fund operations and capital needs into the fourth quarter of 2024. The liquidity note separately says funds should cover the current operating plan for at least the next 12 months from issuance; these statements use different horizons and should be reconciled.
- Management expected to dose the first GPH101 trial patient in the second half of 2022 and anticipated initial proof-of-concept data in 2023. It also intended to file an IND for a second program by mid-2024.
- COVID-19 Omicron-related site staffing and enrollment disruptions had delayed anticipated trial timelines; the filing notes that treatment of the first trial patient was delayed after a prospective participant contracted COVID-19.
- The company expects substantial ongoing losses and expense growth, and may need additional capital. Financing may dilute shareholders or impose debt restrictions; insufficient funding could force delays, reductions or termination of programs.
- Key risks include early-stage clinical and preclinical development, unproven gene-editing safety and efficacy, adverse events or off-target edits, regulatory uncertainty, competition, reliance on third-party and potentially single-source manufacturing, and intellectual-property and license risks.
- Potential contractual obligations include Stanford development, regulatory and commercial milestones and royalties, and IDT regulatory milestones and royalties; none were reported as achieved or probable at quarter-end. No material legal proceedings were reported.
Important facts for investors to verify
- Confirm the issuer and ticker: the supplied filing is Graphite Bio (GRPH), not LENZ Therapeutics.
- Reconcile the stated cash runway into Q4 2024 with the note’s “at least the next 12 months” liquidity statement, and review subsequent cash burn and financing needs.
- Check updates to GPH101 dosing, enrollment, COVID-related delays and the timing and content of anticipated clinical data.
- Assess the $81.0 million Bayside lease commitment, its commencement conditions and expected effect on future cash needs.
- Review the scope, milestones and continuing obligations under the Stanford and IDT licenses, as well as manufacturing supply concentration and intellectual-property exposure.